250 likes | 375 Views
Surgical Research Networks. December 2013. Benefiting from Trials. Improving care for surgical patients Delivering advances in medicine Disseminating best practice. MRC CR07 - Plane of surgery . MRC CR07 3 yr local recurrence by plane of surgery and treatment arm. MP plane.
E N D
Surgical Research Networks December 2013
Benefiting from Trials • Improving care for surgical patients • Delivering advances in medicine • Disseminating best practice
MRC CR07 - Plane of surgery MRC CR07 3 yr local recurrence by plane of surgery and treatment arm MP plane 10% vs16% IM plane 4% vs10% Meso plane 1% vs7%
100 Mesorectal plane Intramesorectal plane Muscularis propria plane 75 Percentage 50 25 0 1998 1999 2000 2001 2002 2003 2004 2005 Year Plane of surgery CRO7
Aim • Create a large nucleus of research active surgeons across a range of specialties
Building Networks Trainee Collaboratives:Experience with Surgical Trials
Background • WMRC • Gen Surgery-Trainee led research group • Clinical research alongside training
Inclusion: All patients undergoing laparotomy Exclusion: Laparoscopic-assisted surgery Online randomisation Blinded wound reviews pre-discharge (5-7 days) and at 30-33 days post-op Funded by NIHR Research for Patient Benefit programme ROSSINI Reduction Of Surgical Site Infection using a Novel Intervention A randomised controlled trial of a wound-edge protection device to reduce surgical site infection
ROSSINI - Sites • Royal Derby Hospital • Wrightington,Wigan and Leigh • Derriford Hospital, Plymouth • Hope Hospital, Salford • Royal Devon and Exeter Hospital • Medway • Maidstone + Tunbridge Wells • Torbay • St Marks, London • Leyton, Mid Cheshire • Nottingham University Hospitals • Stepping Hill, Stockport • University Hospital Birmingham • Russells Hall Hospital • Walsall Manor Hospital • City and Sandwell Hospitals • Heartlands and Good Hope Hospitals • Warwick Hospital • University Hospital North Staffordshire • New Cross Hospital Wolverhampton
Inclusion Criteria: All laparoscopic and open BOWEL surgery for malignant or benign pathology. Primary objective: Does pre-operative dexamethasone reduces post-operative nausea and vomiting (PONV) in patients undergoing elective bowel surgery. Secondary objectives: Are there are other measurable benefits during recovery from surgery with the use of dexamethasone including quicker return to oral diet and reduced length of stay. DexamethasoneReduces Emesis After Major Gastrointestinal Surgery
General Surgical Research Collaboratives Newcastle Surgical Research Collaborative Scottish Surgical Registrars Research Group
AIM • Aim: a national (international), multicentre, audit of appendicectomy • Primary outcome: negative appendicectomy rate • Secondary outcomes: laparoscopy, adverse events • Inclusion: appendicectomy, all ages
Recruitment • 95 centres • 3326 patients • 89 UK centres • 6 international centres
Building the Infrastructure • Open new trials • Engage clinicians • Provide expertise
Clinical Research Initiative Steering Committee Royal College of Surgeons and partners Manchester & Liverpool NWSTC Birmingham BSTC Bristol BSTC Barts NFORSC Oxford SITU Surgical Specialty Leads Orthopaedics, Trauma, Neurosurgery, ENT, head and neck, cardiothoracic, Transplantation Endocrine, Plastics, Colorectal Consultant + Trainee network 1 Consultant + Trainee network 2 Consultant + Trainee network 3 Consultant + Trainee network 4 Consultant + Trainee network 5 Consultant + Trainee network 6
A new era • Specialist trials unit support • Specialty leads • Developing study groups • Developing collaboration • Trainee Networks • Nationwide • Multidisciplinary
Colllaborative team Train Clinicians Governance & Ethics Protocol MHRA Randomise Test Data Sets First in Man Trials International Uptake Regulatory Administration Early Phase Study National Evaluation Innovator HTC Early phase unit Late Phase Trials Unit
Technique • Technique published • Youtube: http://www.youtube.com/watch?v=v7gtLWLzBkY
ROCSS timelines • Phase 1 2012 • Single centre case series • Reported as new technique • Phase II 2013 • 5 sites, randomised closure, 90 patients • International phase III • 30 site in 2014, 450 patients • Reporting 2017